OS Therapies Inc 8-K/A

What Happened
OS Therapies Inc. (OSTX) filed a Form 8-K on July 7, 2026 to furnish exhibits relating to financing arrangements dated June 30, 2026 with Leonite Fund I, LP. The filing references a senior secured convertible promissory note, a common stock purchase warrant, a securities purchase agreement, a pledge and security agreement, a side letter, and a July 2, 2026 press release. The exhibits are filed or incorporated by reference to the company’s earlier Form 8-K filed July 2, 2026. Certain schedules/exhibits were omitted pursuant to Item 601(a)(5) of Regulation S‑K and will be provided to the SEC upon request.

Key Details

• Agreements dated June 30, 2026 among OS Therapies Incorporated, OS Animal Health Inc., OS Therapies UK LTD and Leonite Fund I, LP.
• Exhibits include: Form of Senior Secured Convertible Promissory Note (Ex. 4.1), Common Stock Purchase Warrant (Ex. 4.2), Securities Purchase Agreement (Ex. 10.1), Pledge and Security Agreement (Ex. 10.2), and a Side Letter (Ex. 10.3).
• Press release issued July 2, 2026 is included by reference (Ex. 99.1).
• Cover Page Interactive Data File (Inline XBRL) is included (Ex. 104).

Why It Matters
These exhibits indicate OS Therapies entered financing arrangements with Leonite Fund that could affect the company’s capital structure — potentially adding secured debt, convertible obligations and warrants that may dilute existing equity holders if converted or exercised. The 8-K itself provides exhibit access but does not disclose deal economics in this filing; investors should review the referenced July 2, 2026 Form 8-K and the specific agreements for dollar amounts, conversion terms, security interests, and dilution impact.